Ian Quigley, Leash Bio CEO
August 15, 2024 07:00 AM EDTUpdated 08:09 AM
AI

In a re­al­i­ty check for the field, AI un­der­whelms in Leash Bio's bind­ing con­test: 'No one did well'

Andrew Dunn

Senior Biopharma Correspondent

Ar­ti­fi­cial in­tel­li­gence mod­els may be do­ing a lot more mem­o­riz­ing and a lot less rea­son­ing when it comes to pre­dict­ing bi­ol­o­gy,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Scor­pi­on de­tails ear­ly da­ta on tar­get­ed breast can­cer drug as it seeks to chal­lenge No­var­tis, Roche

Ar­bor Biotech­nolo­gies cuts ear­ly-stage dis­cov­ery work, lays off staff

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster

Up­dat­ed: Bris­tol My­ers touts LAG-3 strat­e­gy in lung can­cer, but da­ta caveats damp­en ex­cite­ment

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

A service from the Financial Times